PARP (Poly ADP - Ribose Polymerase) inhibitors, such as
olaparib, are targeted drugs that
block an enzyme involved in many functions in the cell, including the repair of DNA damage.
The trial compared the activity of the combination of the drug
olaparib, which
blocks DNA repair, and the blood vessel inhibitor drug cediranib, vs.
olaparib alone.